Center for Reproductive Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200135, China.
Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics, Shanghai 200135, China.
Asian J Androl. 2022 May-Jun;24(3):299-304. doi: 10.4103/aja202151.
The extent of spermatogenic impairment on intracytoplasmic sperm injection (ICSI) outcomes and the risk of major birth defects have been little assessed. In this study, we evaluated the relationship between various spermatogenic conditions, sperm origin on ICSI outcomes, and major birth defects. A total of 934 infertile men attending the Center for Reproductive Medicine of Ren Ji Hospital (Shanghai, China) were classified into six groups: nonobstructive azoospermia (NOA; n = 84), extremely severe oligozoospermia (esOZ; n = 163), severe oligozoospermia (sOZ, n = 174), mild oligozoospermia (mOZ; n = 148), obstructive azoospermia (OAZ; n = 155), and normozoospermia (NZ; n = 210). Rates of fertilization, embryo cleavage, high-quality embryos, implantation, biochemical and clinical pregnancies, abortion, delivery, newborns, as well as major birth malformations, and other newborn outcomes were analyzed and compared among groups. The NOA group showed a statistically lower fertilization rate (68.2% vs esOZ 77.3%, sOZ 78.0%, mOZ 73.8%, OAZ 76.6%, and NZ 79.3%, all P < 0.05), but a significantly higher implantation rate (37.8%) than the groups esOZ (30.1%), sOZ (30.4%), mOZ (32.6%), and OAZ (31.0%) (all P < 0.05), which was similar to that of Group NZ (38.4%). However, there were no statistically significant differences in rates of embryo cleavage, high-quality embryos, biochemical and clinical pregnancies, abortions, deliveries, major birth malformations, and other newborn outcomes in the six groups. The results showed that NOA only negatively affects some embryological outcomes such as fertilization rate. There was no evidence of differences in other embryological and clinical outcomes with respect to sperm source or spermatogenic status. Spermatogenic failure and sperm origins do not impinge on the clinical outcomes in ICSI treatment.
精子发生损伤对卵胞浆内单精子注射(ICSI)结局和重大出生缺陷的风险的评估还很有限。在这项研究中,我们评估了各种精子发生情况、精子来源与 ICSI 结局和重大出生缺陷之间的关系。共有 934 名在中国上海仁济医院生殖医学中心就诊的不育男性被分为六组:非梗阻性无精子症(NOA;n=84)、极严重少精子症(esOZ;n=163)、严重少精子症(sOZ,n=174)、轻度少精子症(mOZ;n=148)、梗阻性无精子症(OAZ;n=155)和正常精子症(NZ;n=210)。比较各组间受精率、胚胎分裂率、优质胚胎率、着床率、生化妊娠率、临床妊娠率、流产率、分娩率、新生儿率以及重大出生缺陷和其他新生儿结局。NOA 组的受精率(68.2%比 esOZ 77.3%、sOZ 78.0%、mOZ 73.8%、OAZ 76.6%和 NZ 79.3%,均 P<0.05)显著降低,但着床率(37.8%)明显高于 esOZ(30.1%)、sOZ(30.4%)、mOZ(32.6%)和 OAZ(31.0%)(均 P<0.05),与 NZ 组(38.4%)相似。然而,六组间胚胎分裂率、优质胚胎率、生化妊娠率、临床妊娠率、流产率、分娩率、重大出生缺陷率及其他新生儿结局率均无统计学差异。结果表明,NOA 仅对受精率等一些胚胎学结局产生负面影响。精子来源或精子发生状态与其他胚胎学和临床结局无差异证据。精子发生衰竭和精子来源并不影响 ICSI 治疗的临床结局。